Development of new vaccines against dengue fever and Japanese encephalitis

Intervirology

Volumn 44, Issue 2-3, 2001, Pages 176-197

  Kinney, Richard M ^a   Huang, Claire Y H ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Chimeric virus; Dengue virus; DNA vaccine; Flaviviridae; Flavivirus; Infectious cDNA clone; Japanese encephalitis virus; RNA virus; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; DENGUE VACCINE; DNA VACCINE; ENVELOPE PROTEIN; INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEMBRANE PROTEIN; RECOMBINANT VACCINE; VIRUS PROTEIN;

AEDES AEGYPTI; ALLERGIC REACTION; ARTICLE; CHIMERA; CLONE; CULEX; CYTOTOXIC LYMPHOCYTE; DENGUE; DENGUE VIRUS; EPIDEMIC ENCEPHALITIS; ESCHERICHIA COLI; FLAVIVIRUS; GENETIC ENGINEERING; HUMAN; IMMUNE SYSTEM; JAPANESE ENCEPHALITIS VIRUS; MOSQUITO; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; DENGUE; DENGUE VIRUS; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HUMANS; MOLECULAR SEQUENCE DATA; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT; VIRAL VACCINES;

ARTHROPODA; DENGUE VIRUS; ESCHERICHIA COLI; FLAVIVIRIDAE; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; RNA VIRUSES;

EID: 0034886481     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050045     Document Type: Article

References (189)

1. Flaviviruses
2. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera
3. Phylogeny of the genus Flavivirus
4. Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses
5. Development of dengue and Japanese encephalitis vaccines
6. Vaccine development against dengue and Japanese encephalitis: Report of a World Health Organization Meeting
7. New initiatives for the control of Japanese encephalitis by vaccination: Minutes of a WHO/CVI meeting, Bangkok, October 1998
8. New and improved vaccines for dengue, Japanese encephalitis, and yellow fever viruses
9. Japanese encephalitis and dengue vaccines
10. Recombinant dengue virus vaccines
11. Dengue - An overview
12. Dengue and dengue hemorrhagic fever
13. Live attenuated tetravalent vaccine
14. Common occurrence of concurrent infections by multiple dengue virus serotypes
15. The emperor's new clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever
16. Molecular and in vitro analysis of eight dengue type 2 viruses isolated from patients exhibiting different disease severities
17. Dengue virus structural differences that correlate with pathogenesis
18. Pathogenesis of dengue: Challenge to molecular biology
19. Antibody-dependent enhancement of infection and the pathogenesis of viral disease
20. Bystander target cell lysis and cytokine production by dengue virus-specific CD4+ cytotoxic T-lymphocyte clones
21. Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus
22. Analysis of murine CD8+ T-cell clones specific for the dengue virus NS3 protein: Flavivirus cross-reactivity and influence of infecting serotype
23. Immunopathogenesis of dengue virus infections
24. New mouse model for dengue virus vaccine testing
25. Development of a novel mouse model for dengue virus infection
26. The ecology of Japanese encephalitis virus in the Australian region
27. The epidemiology of Japanese encephalitis: Prospects for prevention
28. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains
29. Antigenic and genetic variation among Japanese encephalitis virus strains belonging to genotype 1
30. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus
31. Flaviviridae
32. Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution
33. Nucleotide and complete amino acid sequences of Kunjin virus: Definitive gene order and characteristics of the virus-specified proteins
34. Positive identification of NS4A, the last of the hypothetical nonstructural proteins of flaviviruses
35. Flavivirus genome organization, expression, and replication
36. Analyses of the terminal sequences of West Nile virus structural proteins and of the in vitro translation of these proteins allow the proposal of a complete scheme of the proteolytic cleavages involved in their synthesis
37. The envelope glycoprotein from tickborne encephalitis virus at 2 Å resolution
38. Oligomeric rearrangement of tickborne encephalitis virus envelope proteins induced by an acidic pH
39. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein
40. In vitro processing of dengue virus structural proteins: Cleavage of the pre-membrane protein
41. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis
42. Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication
43. Mutagenesis of the N-linked glycosylation site of the yellow fever virus NS1 protein: Effects on virus replication and mouse neurovirulence
44. Genetic analysis of the yellow fever virus NS1 protein: Identification of a temperature-sensitive mutation which blocks RNA accumulation
45. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: Identification of a domain required for NS2B-NS3 protease activity
46. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity
47. Dengue virus NS3 protease. Crystal structure and insights into interactions of the active site with substrates by molecular modeling and structural analysis of mutational effects
48. Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes
49. Dengue virus-specific HLA-B35- restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones
50. + T-cell clones: Flavivirus cross-reactivity, protein recognition, and cytotoxic activity
51. Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice
52. Particulate vaccine candidate for Japanese encephalitis induces long-lasting virus-specific memory T lymphocytes in mice
53. Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates
54. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: Quantitation of the dengue virus-specific CD8 T-cell response
55. The flavivirus nonstructural protein NS3 is a dominant source of cytotoxic T cell peptide determinants
56. Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2,3, and 4
57. Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary virus infection
58. Immunochemistry of dengue viruses
59. Identification of peptides mimicking the antigenicity and immunogenicity of conformational epitopes on Japanese encephalitis virus protein using synthetic peptide libraries
60. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology
61. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys
62. Protection against Japanese encephalitis by inactivated vaccines
63. Systemic immediatetype reactions to gelatin included in Japanese encephalitis vaccines
64. Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines
65. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti
66. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti
67. Dengue-2 vaccine: Infection of Aedes aegypti mosquitoes by feeding on viremic recipients
68. Dengue-2 vaccine: Oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti
69. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: A possible marker of human attenuation
70. Research on dengue during World War II
71. Transmission of neurotropic yellow fever virus by Stegomyia mosquitoes
72. Failure of Aedes aegypti to transmit yellow fever cultured virus (17D)
73. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus
74. Comparative infection and transmission rates of Japanese encephalitis vaccine (2-8 strain) and parent (SA 14 strain) viruses in Culex tritaeniorhynchus mosquitoes
75. Dengue virus vaccine development: Study on biological markers of uncloned dengue 1 -4 viruses serially passaged in primary kidney cells
76. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host
77. Virological surveillance for dengue haemorrhagic fever in Indonesia using the mosquito inoculation technique
78. Live attenuated tetravalent dengue vaccine
79. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers
80. The neurovirulence of flaviviruses in crab eating monkeys (Macaca fascicularis)
81. Neurovirulence detection of dengue virus using rhesus and cynomolgus monkeys
82. Neurovirulence effects of dengue-2 viruses on the rhesus (Macaca mulatta) brain and spinal cord
83. Dengue-4 vaccine: Neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys
84. Dengue-3 (16562) PGMK 33 vaccine: Neurovirulence, viremia and immune responses in Macaca fascicularis
85. Construction of infectious cDNA clones for dengue 2 virus: Strain 16681 and its attenuated vaccine derivative, strain PDK-53
86. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3
87. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine
88. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK-53)in ten American volunteers
89. Dengue virus specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine
90. Study of bivalent dengue vaccine in volunteers
91. Comparison of nucleotide and deduced amino acid sequence of the 5′ non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives
92. Japanese encephalitis virus live attenuated vaccine, Chinese strain SA14-14-2: Adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use
93. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14- 2): A case control study
94. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA
95. Nucleotide sequence of the virulent SA- 14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-2
96. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14
97. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it
98. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation
99. Construction of a full-length infectious clone for dengue- 1 virus Western Pacific, 74 strain
100. Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast
101. Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain)
102. Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genome- length cDNA
103. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus
104. Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-ligated cDNA templates
105. Completion of Kunjin virus RNA sequence and recovery of an infectious RNA transcribed from stably cloned full-length cDNA
106. Characterization of infectious Murray Valley encephalitis virus derived from a stably cloned genome-length cDNA
107. Infectious cDNA clones of tickborne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr
108. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes
109. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge
110. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice
111. Evaluation of molecular strategies to develop a live dengue vaccine
112. Construction and characterization of chimeric tickborne encephalitis/dengue type 4 viruses
113. Chimeric tickborne encephalitis and dengue type 4 viruses: Effects of mutations on neurovirulence in mice
114. Genetic determinants of dengue type 4 virus neurovirulence for mice
115. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence
116. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome
117. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys
118. Nucleotide sequence of dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses
119. Partial nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue virus type 2, New Guinea C and PUO-218 strains
120. Recombinant chimeric yellow fever-dengue 2 virus is immunogenic and protective in nonhuman primates
121. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis
122. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties
123. Conserved elements in the 3′ untranslated region of flavivirus RNAs and potential cyclization sequences
124. A novel in vitro replication system for dengue virus
125. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (Chimeri- Vax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis
126. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14- 14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
127. NYVAC: A highly attenuated strain of vaccinia virus
128. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
129. Applications of canarypox (ALVAC)vectors in human and veterinary vaccination
130. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells
131. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection
132. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus
133. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection
134. Avipox virus-vectored Japanese encephalitis virus vaccines: Use as vaccine candidates in combination with purified subunit immunogens
135. A highly attenuated host range-restricted vaccinia virus strain, NY- VAC, encoding the prM, E and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine
136. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys
137. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes
138. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge
139. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein: Long-term protection and effect of revaccination
140. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection
141. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice
142. Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein
143. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice
144. Induction of protective immunity against dengue virus type 2: Comparison of candidate live attenuated and recombinant vaccines
145. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and non-structural proteins: Evidence of priming and partial protection
146. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice
147. DNA- based vaccines: Extending the technology
148. Immunisation with DNA polynucleotides protects mice against lethal challenge with St.Louis encephalitis virus
149. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge
150. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long- lived and protective immunity against the flavivirus, Murray Valley encephalitis virus
151. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies
152. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice
153. Screening of protective antigens of Japanese encephalitis virus by DNA immunization: A comparative study with conventional viral vaccines
154. Induction of protective immunity against Japanese encephalitis with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes
155. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes
156. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and longlasting antibodies in swine
157. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice
158. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice
159. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys
160. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses
161. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein
162. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques
163. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice
164. Protection of mice against dengue 2 virus encephalitis by immunization with dengue 2 virus non-structural gycoprotein NS1
165. Transformation by viruses: Simian virus 40 as a model system
166. DNA and RNA-based vaccines: Principles, progress and prospects
167. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
168. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants
169. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
170. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes
171. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity
172. Modulatory effects of the human heat shock protein 70 on DNA vaccination
173. DNA immunization of infants: Potential and limitations
174. Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization
175. Persistence of neutralizing antibody to yellow fever virus 30 to 35 years following immunization with 17D yellow fever vaccine: A study of World War II veterans in 1975-1976
176. Yellow fever vaccine
177. Persistence of antibody in human subjects for 7 to 10 years following administration of combined live attenuated measles, mumps and rubella virus vaccines
178. Experience with Vero cells at Pasteur Mérieux Connaught
179. Phylogenetic evidence for recombination in dengue virus
180. Widespread intra-serotype recombination in natural populations of dengue virus
181. Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status
182. Dengue virus type 2 vaccine: Reactogenicity and immunogenicity in soldiers
183. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine
184. Japanese encephalitis vaccine (inactivated, BIKEN)in U.S. soldiers: Immunogenicity and safety of vaccine administered in two dosing regimens
185. The introduction of new vaccines into developing countries
186. Sindbis vectors suppress secretion of subviral particles of Japanese encephalitis virus from mammalian cells infected with SIN-JEV recombinants
187. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection
188. Defective adenoviruses as novel vaccines for the Flaviviridae
189. Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1